<DOC>
	<DOCNO>NCT00875264</DOCNO>
	<brief_summary>The primary objective study determine maximum tolerate dose ( MTD ) dose-limiting toxicity CEP-11981 patient advance , relapsed/refractory solid tumor .</brief_summary>
	<brief_title>Open-Label Study Determine Maximum Tolerated Oral Dose Kinase Inhibitor CEP-11981 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Key The patient : histologically cytologically confirm solid tumor relapse refractory . Additionally , tumor must consider unresponsive poorly responsive accept treatment modality . life expectancy least 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 , 2. normal neurologic examination finding . Patients neurologic sign symptom indicative brain metastasis must undergo magnetic resonance imaging ( MRI ) rule brain metastasis . fully recover prior surgical procedure ( ) . fully recover reversible side effect prior therapy cancer include radiation therapy , chemotherapy , immunotherapy . appropriate health determine medical psychiatric history , medical examination , electrocardiography ( ECG ) , serum chemistry hematology test , urinalysis . woman childbearing potential ( surgically sterile 2 year postmenopausal ) , must use medically accept method contraception must agree continue use method duration study 30 day participation study . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . man , surgically sterile capable produce offspring , must practice abstinence use barrier method birth control , must agree continue use method duration study 30 day participation study . willing able comply study restriction return clinic evaluation ( include followup ) . Key The patient : follow hematologic value : absolute neutrophil count ( ANC ) less 1500/mm3 , platelet count less 100000/mm3 , hemoglobin le 9 g/dL . follow hepatic function value : bilirubin great 1.5 time upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 2.0 time ULN absence know hepatic metastasis , ALT AST great 3.0 time ULN presence know hepatic metastasis . serum creatinine value great 1.5 mg/dL . know cerebral metastasis . currently warfarin heparin therapy . preexist coagulopathy , recent hemoptysis , gross hematuria , gastrointestinal bleeding , history clinically significant cardiovascular cerebrovascular event within 6 month prior study entry . uncontrolled hypertension define blood pressure measurement great 150 mm Hg systolic 90 mm Hg diastolic medication . receive antineoplastic treatment solid tumor . ( Continuing hormonal treatment permit . ) receive investigational drug within past 4 week . previously enrol study receive CEP11981 . know hypersensitivity gelatin lactose monohydrate . woman pregnant lactating . take medication know potent inducer CYP1A2 , CYP2C8 , CYP3A4 within 4 week prior first dose study drug . take medication know potent inhibitor CYP1A2 , CYP2C8 , CYP3A4 within 2 week prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>CEP-11981</keyword>
	<keyword>TIE-2</keyword>
	<keyword>VEGF-R</keyword>
</DOC>